002821.SZ
Asymchem Laboratories (Tianjin) Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 156.57
−6.86%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 7.1B | 6.7B | 5.8B | 7.8B | 10.3B |
| Cost of Revenue | 4.2B | 3.9B | 3.3B | 3.8B | 5.4B |
| Gross Profit | 2.9B | 2.8B | 2.5B | 4.0B | 4.9B |
| Operating Expenses | |||||
| R&D Expense | 553.1M | 593.3M | 614.5M | 707.9M | 708.9M |
| SG&A Expense | (89.2M) | — | — | — | — |
| General & Admin Expense | 521.3M | 764.8M | 825.2M | 788.5M | 805.5M |
| Selling & Marketing Expense | 154.3M | 210.4M | 243.4M | 196.4M | 150.2M |
| Other Expenses | 334.6M | — | — | — | — |
| Total Operating Expenses | 1.7B | 1.6B | 1.5B | 1.6B | 1.2B |
| Cost and Expenses | 5.9B | 5.4B | 4.8B | 5.4B | 6.6B |
| Operating Income (EBIT) | 1.3B | 1.3B | 1.1B | 2.6B | 3.7B |
| Non-Operating | |||||
| Interest Income | 40.1M | — | — | — | — |
| Interest Expense | 3.2M | — | — | — | — |
| Net Interest Income | 36.9M | — | — | — | — |
| Other Non-Op Income/Expense | (98.0M) | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 1.2B | 1.3B | 1.1B | 2.6B | 3.7B |
| Income Tax Expense | 145.0M | 159.7M | 136.6M | 306.3M | 430.3M |
| Bottom Line | |||||
| Net Income | 1.0B | 1.1B | 949.0M | 2.3B | 3.3B |
| Earnings from Cont. Ops | 1.0B | 1.1B | 935.8M | 2.3B | 3.3B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 1.0B | 1.1B | 949.0M | 2.3B | 3.3B |
| Per Share | |||||
| Basic EPS | CN¥2.88 | CN¥3.16 | CN¥2.69 | CN¥6.26 | CN¥9.02 |
| Diluted EPS | CN¥2.88 | CN¥3.16 | CN¥2.69 | CN¥6.26 | CN¥9.00 |
| Revenue Per Share | CN¥19.88 | CN¥18.61 | CN¥16.45 | CN¥21.59 | CN¥28.02 |
| Shares | |||||
| Basic Shares Outstanding | 356.2M | 358.4M | 352.8M | 362.4M | 366.0M |
| Diluted Shares Outstanding | 356.2M | 358.4M | 352.8M | 362.4M | 366.0M |
| Profitability Metrics | |||||
| EBITDA | 511.1M | 1.8B | 1.6B | 3.0B | 4.1B |
| D&A | 161.0M | 516.3M | 480.3M | 450.7M | 362.0M |
| EBIT | 351.9M | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026